Zaidi, A.A. and Vesole, D.H. (2001) Multiple myeloma: an old disease with new hope for the future. CA Cancer J. Clin. 51, 273-285
Kaufman, J. and Lonial, S. (2004) Multiple myeloma: the role of transplant and novel treatment strategies. Semin. Oncol. 31 (2 Suppl. 4), 99-105
Dalton, W.S. (2003) The tumor microenvironment: focus on myeloma. Cancer Treat. Rev. 29 (Suppl. 1), 11-19
Roodman, G.D. (2002) Role of the bone marrow microenvironment in multiple myeloma. J. Bone Miner. Res. 17, 1921-1925
Vanderkerken, K. et al. (2003) Multiple myeloma biology: lessons from the 5TMM models. Immunol. Rev. 194, 196-206
Hideshima, T. et al. (2003) Novel therapeutic approaches for multiple myeloma. Immunol. Rev. 194, 164-176
Vanderkerken, K. et al. (2000) Homing of the myeloma cell clone. Acta Oncol. 39, 771-776
Van Riet, I. et al. (2003) Endothelial cell-tumor interactions in multiple myeloma. Hematol. J. 4 (Suppl. 1), S40
Drexler, H.G. and Matsuo, Y. (2000) Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk. Res. 24, 681-703
Nilsson, K. and Ponten, J. (1975) Classification and biological nature of established human hematopoietic cell lines. Int. J. Cancer 15, 321-341
Pellat-Deceunynk, C. et al. (1995) Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86, 4001-4002
Drexler, H.G. et al. (2001) Cross-contamination: HS-Sultan is not a myeloma but a Burkitt lymphoma cell line. Blood 98, 3495-3496
Rawstron, A.C. et al. (1997) Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br. J. Haematol. 97, 46-55
Lin, P. et al. (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol. 121, 482-488
Gado, K. et al. (2001) Mouse plasmacytoma: an experimental model of human multiple myeloma. Haematologica 86, 227-236
Radl, J. (1999) Multiple myeloma and related disorders. Lessons from an animal model. Pathol. Biol. 47, 109-114
Asosingh, K. et al. (2000) The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol. J. 1, 351-356
Menu, E. et al. (2004) Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol. Dis. 33, 111-119
Van Valckenborgh, E. et al. (2002) Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br. J. Cancer 86, 796-802
Croucher, P.I. et al. (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98, 3534-3540
Croucher, P.I. et al. (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res. 18, 482-492
Vanderkerken, K. et al. (2003) Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 63, 287-289
Van Valckenborgh, E. et al. (2004) Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Am. J. Pathol. 165, 869-878
Bankert, R.B. et al. (2001) Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. 22, 386-393
Lozupone, F. et al. (2000) Murine granulocytes control human tumor growth in SCID mice. Int. J. Cancer 87, 569-573
Miyakawa, Y. et al. (2004) Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem. Biophys. Res. Commun. 313, 258-262
Gaugler, M.H. et al. (1998) Characterization of the response of human bone marrow endothelial cells to in vitro irradiation. Br. J. Haematol. 103, 980-989
Hopewell, J.W. (2003) Radiation-therapy effects on bone density. Med. Pediatr. Oncol. 41, 208-211
Huang, Y.W. et al. (1993) Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res. 53, 1392-1396
Tsunenari, T. et al. (1997) New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 90, 2437-2444
Hjorth-Hansen, H. et al. (1999) Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J. Bone Miner. Res. 14, 256-263
Feo-Zuppardi, F.J. et al. (1992) Long-term engraftment of fresh human myeloma cells in SCID mice. Blood 80, 2843-2850
Pilarski, L.M. et al. (2000) Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95, 1056-1065
Cuendet, M. et al. (2004) Multiple myeloma regression mediated by bruceantin. Clin. Cancer Res. 10, 1170-1179
Tassone, P. et al. (2004) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1- oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 64, 4629-4636
Uneda, S. et al. (2003) A nitric oxide synthase inhibitor, N(G)-nitro-L-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. Br. J. Haematol. 120, 396-404
Dingli, D. et al. (2002) Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin. Cancer Res. 8, 3948-3954
Yaccoby, S. et al. (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92, 2908-2913
Yaccoby, S. et al. (2002) Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 100, 4162-4168
Huang, S.Y. et al. (2004) Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system. Am. J. Pathol. 164, 747-756
